SMTL Dressings Datacard

Product Name:	**QUINABAND**
Classification Name:	**Bandage Zinc Paste, Calamine and Clioquinol BP**
Manufacturer:	**Seton Healthcare Group plc**

Description

Quinaband consists of an open-wove bleached cotton bandage impregnated evenly with a paste of:

- Zinc Oxide BP 9.25%
- Clioquinol BP 1.00%
- Calamine BP 5.75%
- Modified Starch 14.60%
- Citric Acid BP 2.00%
- Glycerine BP 30.20%
- Castor Oil BP 1.00%
- Teepol 0.0652%
- Phenoxyethanol 1.00%
- Water to 100.0%

The bandage is yellow in colour and supplied rolled ready for use.

Indications

Quinaband is used in the management of venous and gravitational ulcers as an adjunct to compression therapy. Quinaband will reduce the odour often associated with such ulcers, and is particularly useful if the ulcer[*** linked ul-ns-00 ***] is infected.

Contra-Indications

Quinaband is contra-indicated for use on patients with existing or suspected thyroid disorders and should not be applied to patients known to be sensitive to one of the ingredients of the dressing. Quinaband should not be applied to acute eczematous lesions.

Method of use

Quinaband should be applied to the leg in a series of loose folds rather than a continuous spiral to ensure that it cannot constrict blood flow or cause a tourniquet effect. When used in the treatment of venous leg ulcers, Quinaband should be used in conjunction with a suitable compression bandage to aid venous return and to prevent the paste bandage from drying out. In conditions where compression is not required, Quinaband should be covered with a non-elasticated tubular bandage to reduce drying out and to prevent the soiling of clothing.

Frequency of Change

Quinaband may be renewed as frequently as the condition requires.

Warnings

The use of Quinaband bandages may result in elevation of serum protein bound iodine (PBI) levels; if thyroid disease is suspected both PBI and the absolute concentrations of free serum-thyroxine should be monitored. The use of Quinaband during pregnancy and lactation is also not recommended as iodides absorbed may affect the foetal or neonatal thyroid. Some patients, particularly those with leg ulcers, have skin that is easily sensitised to topical medicaments including the preservatives used in the formulation of some paste bandages. If changes occur in the appearance of skin surrounding an ulcer dressed with Quinaband, sensitisation should be suspected. Such patients should be referred for specialist diagnosis including patch testing. One of the functions of occlusive bandages is to increase absorption of topical medicaments. Care should therefore be taken if topical steroid preparations are used under these bandages as their absorption may be significantly increased.

Presentation

The bandage is presented wrapped in waxed paper, sealed in an air tight polythene pouch within a cardboard carton.

Storage

An expiry date is printed on each package. Quinaband should be stored in a dry place not exceeding 25 °C.

Sizes

7.5 cm x 6 m

Quinaband is available on Drug Tariff.

Legal Category

Pharmacy [P]

Revision Details

Revision Author	Dr S. Thomas
Revision No	1.3
Revision date	1997/12/16

Please inform SMTL of any inaccuracies or changes required in this datacard.

Disclaimer

This datacard has been prepared as an aid to contracting for purchasers in the NHS in Wales, and should not be used as a substitute for literature, instructions or training from the manufacturers of the devices.